Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAIC + targeted therapy + pd-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Peking University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intra-arterial, Intravenous, Oral
01
Overview
The combination regimen of Hepatic Arterial Infusion Chemotherapy (HAIC), targeted therapy, and a PD-1 inhibitor is an investigational salvage treatment strategy for patients with microsatellite stable (MSS) advanced colorectal cancer liver metastasis (CRCLM) who have failed standard systemic therapy. As specifically evaluated in the SALVLIV trial (NCT06199232) by Peking University, the regimen consists of three primary components: (1) HAIC, which delivers high-dose cytotoxic agents such as oxaliplatin and 5-fluorouracil (or the FOLFOXIRI triplet) directly into the hepatic artery to maximize local drug concentration in liver tumors; (2) a targeted therapy component, typically the VEGFR1-3 inhibitor fruquintinib or KL-140, selected based on ctDNA genotyping; and (3) the anti-PD-1 monoclonal antibody tislelizumab. This triplet approach aims to overcome the immunosuppressive microenvironment of MSS colorectal cancer by combining direct cytotoxic effects, anti-angiogenesis, and immune checkpoint blockade.
- Brand names
- TevimbraFruzaqla
- Other names
- SALVLIV regimenctDNA genotyping-guided targeted therapy combined with tislelizumab and HAIC
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)RNR (Ribonucleotide reductase)VEGFR4 (Vascular endothelial growth factor Receptor-3)RET (Rearranged during transfection receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)FGFR (FGFR family)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on HAIC + targeted therapy + pd-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAIC + targeted therapy + pd-1 inhibitor.